Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590290 | 0.79 | NPC1 (0.50) | NPC1RAB9AGPR119HDAC6 | |
| SCHEMBL2584790 | 0.79 | GPR119 (0.67) | GPR119HDAC6 | |
| SCHEMBL23387567 | 0.78 | NPC1 (0.59) | NPC1RAB9AHDAC6 | |
| SCHEMBL2245678 | 0.78 | NPC1 (1.00) | NPC1RAB9AGPR119HDAC6 | |
| SCHEMBL26686912 | 0.78 | NPC1 (0.64) | NPC1RAB9AGPR119HDAC6 | |
| SCHEMBL19029290 | 0.74 | HDAC6 (0.98) | NPC1RAB9AHDAC6 | |
| SCHEMBL21352568 | 0.74 | HDAC6 (1.00) | NPC1RAB9AHDAC6 | |
| SCHEMBL25625025 | 0.73 | HDAC6 (0.59) | HDAC6TLR9TLR7MAOB | |
| SCHEMBL2582987 | 0.73 | ESR2 (0.76) | NPC1RAB9AGPR119HDAC6 | |
| SCHEMBL2582851 | 0.73 | NPC1 (0.63) | NPC1RAB9AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566864-B1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| EP-2566864-A2 | PYRIDAZINONES AS GPR119 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138427-A2 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | GPR65, GPR119, GPR55 | NPC1 2612/4885RAB9A 1318/4885GPR119 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.